ArticleJournal of neuroimmunology2011
Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate.
Article in Journal of neuroimmunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 51 citations in OpenAlex.
- The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis.JAMA neurology · 2014Trial
- Intruders or protectors - the multifaceted role of B cells in CNS disorders.Frontiers in cellular neuroscience · 2023Review
- The role of B cells in the immunopathogenesis of multiple sclerosis.Immunology · 2020Review
- Review
- Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function.International journal of molecular sciences · 2017Review
- B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.CNS drugs · 2016Review
- Treatment of ongoing autoimmune encephalomyelitis with activated B-cell progenitors maturing into regulatory B cells.Nature communications · 2016Article
- Regulatory T Cell Dysfunction Acquiesces to BTLA+ Regulatory B Cells Subsequent to Oral Intervention in Experimental Autoimmune Encephalomyelitis.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets.Neurology(R) neuroimmunology & neuroinflammation · 2016Article
- Article
- Neurotrophins and B-cell malignancies.Cellular and molecular life sciences : CMLS · 2016Review
- Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10.Cytokine · 2015Review
- The gut microbiome in multiple sclerosis.Current treatment options in neurology · 2015Article
- Repetitive hypoxic preconditioning induces an immunosuppressed B cell phenotype during endogenous protection from stroke.Journal of neuroinflammation · 2014Article
- Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?Human vaccines & immunotherapeutics · 2014Review
- Amino acid copolymers that alleviate experimental autoimmune encephalomyelitis in vivo interact with heparan sulfates and glycoprotein 96 in APCs.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- B-cell targeting agents in the treatment of multiple sclerosis.Current treatment options in neurology · 2013Article
- Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis.Journal of neuroimmunology · 2013Article
- B cells and antibodies in multiple sclerosis pathogenesis and therapy.Nature reviews. Neurology · 2012Review
- What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?International journal of molecular sciences · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
We recently showed that B cells reduce CNS inflammation in mice with experimental allergic encephalomyelitis (EAE). Here, we demonstrate that adoptively transferred CD5/CD19+ B cells protect against EAE severity. Furthermore, we show that glatiramer acetate (GA), a therapeutic for relapsing multiple sclerosis treatment, amplifies this effect. Transfer of GA-conditioned B cells leads to increased production of immunoregulatory cytokines and reduced CNS inflammation, as well as decreased expression of the chemokine receptor, CXCR5, and elevated BDNF expression in the CNS. Thus B cells can protect against EAE, and GA augments this effect in maintaining immune homeostasis and controlling EAE disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.